Trademarkia Logo

Canada

C$
ULIBDI
APPROVED

on 30 Apr 2025

Last Applicant/ Owned by

Prometheus Biosciences, Inc.

3050 Science Park Rd.San Diego CA 92037

US

Serial Number

2269038 filed on 21st Feb 2023

Correspondent Address

BORDEN LADNER GERVAIS LLP

Bay Adelaide Centre, East Tower22 Adelaide St. WestTORONTO

ONTARIO

CA

M5H4E3

ULIBDI

Trademark usage description

pharmaceutical preparations used for the treatment of gastrointestinal disorders and diseases, colitis, crohn's disease, inflammatory bowel disease, s Read More

Classification Information


Class [005]
Pharmaceutical preparations used for the treatment of gastrointestinal disorders and diseases, colitis, Crohn's disease, Inflammatory Bowel Disease, systemic sclerosis, Interstitial Lung Disease, Systemic sclerosis-associated interstitial lung disease, arthritis, and other diseases of the immune, digestive, bowel, skin, joint, lung, liver, kidney, bile duct, or gastrointestinal systems, immune modulation and management of side effects associated with renal disorders and cancer; diagnostic preparations for clinical or medical laboratory use; diagnostic reagents for clinical or medical laboratory use.


Classification kind code

12

Class [042]
Medical laboratory services, namely, medical diagnostic testing, and medical research services; medical laboratory services, namely, laboratory testing in the field of disease management and pathology and of patient diagnosis and patient selection.


Classification kind code

12

Class [044]
Disease management services namely medical analysis services for diagnostic and treatment purposes and managing patient data; medical services, namely, providing medical information related to the diagnosis, prevention and treatment of gastrointestinal diseases, colitis, Crohn's disease, Inflammatory Bowel Disease, systemic sclerosis, Interstitial Lung Disease, Systemic sclerosis-associated interstitial lung disease, arthritis, and other diseases of the immune, digestive, bowel, skin, joint, lung, liver, kidney, bile duct, or gastrointestinal systems via computer networks; providing health information in the field of gastrointestinal diseases, colitis, Crohn's disease, Inflammatory Bowel Disease, systemic sclerosis, Interstitial Lung Disease, Systemic sclerosis-associated interstitial lung disease, arthritis, and other diseases of the immune, digestive, bowel, skin, joint, lung, liver, kidney, bile duct, or gastrointestinal systems; providing information relating to medical diagnostic testing; medical consultation in the fields of gastrointestinal diseases, colitis, Crohn's disease, Inflammatory Bowel Disease, systemic sclerosis, Interstitial Lung Disease, Systemic sclerosis-associated interstitial lung disease, arthritis, and other diseases of the immune, digestive, bowel, skin, joint, lung, liver, kidney, bile duct, or gastrointestinal systems; providing information about services for the diagnosis, prevention, and treatment of gastrointestinal disorders and diseases, colitis, Crohn's disease, Inflammatory Bowel Disease, systemic sclerosis, Interstitial Lung Disease, Systemic sclerosis-associated interstitial lung disease, arthritis, and other diseases of the immune, digestive, bowel, skin, joint, lung, liver, kidney, bile duct, or gastrointestinal systems, immune modulation and management of side effects associated with renal disorders and cancer.


Classification kind code

12

Mark Details


Serial Number

2269038

Mark Type

Trademark

Legal History


Show more

Action TakenStatus
Submitted for opposition 22
on 29th Oct 2024
Search Recorded
Submitted for opposition 20
on 29th Oct 2024
Examiner's First Report
Submitted for opposition 223
on 29th Oct 2024
Total Provisional Refusal
Submitted for opposition 256
on 13th May 2024
Notification of Possible Opposition Sent
Submitted for opposition 48
on 15th Mar 2024
Agent Changed
Submitted for opposition 257
on 13th Jul 2023
Designation Notification - Madrid Protocol
Submitted for opposition 1
on 12th Jul 2023
Created
Submitted for opposition 31
on 12th Jul 2023
Formalized
Submitted for opposition 30
on 21st Feb 2023
Filed
Submitted for opposition 228
on 21st Feb 2023
International Registration

This website uses cookies

We use cookies to ensure you get the best experience. Check our Privacy Policy and Terms & Conditions.
Manage cookies

Manage cookies

You can choose to enable or disable some or all of these cookies but disabling some of them may affect your browsing experience.

Advertisement

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously

Analytics

Analytical cookies are used to understand how visitors interact with the website.

Functional

Functional cookies help perform certain functionalities like collecting feedback, and other third-party features.

Performance

Performance cookies are used to understand and analyze the key performance indexes of the website.